IL34抗体 新品

+ +

•  

   

     Immunofluorescence analysis of U251 cells using IL34 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of K562 cells using IL34 mouse mAb (green) and negative control (purple).    

  
  

Interleukin-34 (IL-34) is a cytokine discovered in 2008. known for binding to the colony-stimulating factor 1 receptor (CSF1R) and sharing functional overlap with macrophage colony-stimulating factor (CSF-1). IL-34 plays critical roles in regulating monocyte survival, differentiation, and tissue-specific macrophage homeostasis. It is implicated in various physiological and pathological processes, including neurodevelopment, inflammation, and immune regulation. Dysregulation of IL-34 has been linked to diseases such as rheumatoid arthritis, cancer, and neurodegenerative disorders.

IL-34 antibodies are tools developed to detect, neutralize, or modulate IL-34 activity in research and therapeutic contexts. Polyclonal and monoclonal IL-34 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study IL-34 expression patterns in tissues or disease models. Neutralizing antibodies, in particular, help elucidate IL-34's role in CSF1R signaling and its crosstalk with pathways involved in tumor microenvironment modulation, osteoclastogenesis, and inflammatory responses. Recent studies explore IL-34 antibodies as potential therapeutics, targeting pathways involved in cancer progression (e.g., tumor-associated macrophage recruitment) or autoimmune diseases. However, challenges remain in optimizing specificity and minimizing off-target effects. Ongoing research aims to refine antibody engineering for clinical applications, including bispecific designs or combination therapies targeting IL-34/CSF1R axis components.